Financial Contrast: Bioxytran (OTCMKTS:BIXT) and Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) and Bioxytran (OTCMKTS:BIXT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Vanda Pharmaceuticals and Bioxytran, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	0	0	2	0	3.00
Bioxytran	0	0	0	0	0.00

Vanda Pharmaceuticals currently has a consensus price target of $15.50, indicating a potential upside of 236.96%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Vanda Pharmaceuticals is more favorable than Bioxytran.

Profitability

This table compares Vanda Pharmaceuticals and Bioxytran’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-8.59%	-3.02%	-2.52%
Bioxytran	N/A	N/A	-2,106.99%

Earnings and Valuation

This table compares Vanda Pharmaceuticals and Bioxytran”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$190.86 million	1.41	$2.51 million	($0.28)	-16.43
Bioxytran	N/A	N/A	-$4.28 million	($0.01)	-9.84

Vanda Pharmaceuticals has higher revenue and earnings than Bioxytran. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Bioxytran, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vanda Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Bioxytran has a beta of -0.55, indicating that its stock price is 155% less volatile than the S&P 500.

Insider and Institutional Ownership

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 8.9% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 70.0% of Bioxytran shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Vanda Pharmaceuticals beats Bioxytran on 8 of the 13 factors compared between the two stocks.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.